KRN-633 is primarily utilized in cancer research due to its potent inhibitory effects on vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. By targeting these receptors, it effectively hinders angiogenesis, the process by which new blood vessels form from pre-existing vessels. This is crucial in cancer therapy as tumors require a steady supply of blood to grow and metastasize. By blocking this vascular supply, KRN-633 can potentially starve the tumor, inhibiting its growth and spread. Researchers often employ this compound in preclinical studies to explore its efficacy and mechanism of action in various cancer models, aiming to develop novel anti-cancer therapies that can be translated into clinical applications. Additionally, its role in angiogenesis makes it a valuable tool in studying other diseases characterized by abnormal blood vessel growth, such as certain eye disorders and inflammatory conditions.